胰腺导管腺癌：免疫相关方面综述。
Pancreatic ductal adenocarcinoma: a review of immunologic aspects.
机构信息
Masters Program in Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
出版信息
J Investig Med. 2012 Apr;60(4):643-63. doi: 10.2310/JIM.0b013e31824a4d79.
Abstract
With the continued failures of both early diagnosis and treatment options for pancreatic cancer, it is now time to comprehensively evaluate the role of the immune system on the development and progression of pancreatic cancer. It is important to develop strategies that harness the molecules and cells of the immune system to treat this disease. This review will focus primarily on the role of immune cells in the development and progression of pancreatic ductal adenocarcinoma and to evaluate what is known about the interaction of immune cells with the tumor microenvironment and their role in tumor growth and metastasis. We will conclude with a brief discussion of therapy for pancreatic cancer and the potential role for immunotherapy. We hypothesize that the role of the immune system in tumor development and progression is tissue specific. Our hope is that better understanding of this process will lead to better treatments for this devastating disease.
摘要
由于胰腺癌的早期诊断和治疗选择持续失败，现在是时候全面评估免疫系统在胰腺癌发展和进展中的作用了。重要的是要制定利用免疫系统的分子和细胞来治疗这种疾病的策略。这篇综述将主要关注免疫细胞在胰腺导管腺癌发展和进展中的作用，并评估已知的免疫细胞与肿瘤微环境的相互作用及其在肿瘤生长和转移中的作用。最后，我们将简要讨论胰腺癌的治疗方法和免疫疗法的潜在作用。我们假设免疫系统在肿瘤发生和发展中的作用是组织特异性的。我们希望更好地了解这一过程将为这种毁灭性疾病带来更好的治疗方法。
相似文献
1
Pancreatic ductal adenocarcinoma: a review of immunologic aspects.胰腺导管腺癌：免疫相关方面综述。
J Investig Med. 2012 Apr;60(4):643-63. doi: 10.2310/JIM.0b013e31824a4d79.
2
Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.胰腺导管腺癌免疫治疗的合理联合方案
Chin Clin Oncol. 2017 Jun;6(3):31. doi: 10.21037/cco.2017.06.04.
3
An Immunological Glance on Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌的免疫学观察。
Int J Mol Sci. 2020 May 8;21(9):3345. doi: 10.3390/ijms21093345.
4
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?免疫疗法在胰腺导管腺癌中的应用：一种新兴实体？
Ann Oncol. 2017 Dec 1;28(12):2950-2961. doi: 10.1093/annonc/mdx503.
5
Genetics and biology of pancreatic ductal adenocarcinoma.胰腺导管腺癌的遗传学与生物学
Genes Dev. 2025 Jan 7;39(1-2):36-63. doi: 10.1101/gad.351863.124.
6
Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies.胰腺导管腺癌中的中性粒细胞：将临床前研究进展转化为改善治疗策略的临床前景。
Expert Rev Clin Immunol. 2024 Aug;20(8):945-958. doi: 10.1080/1744666X.2024.2348605. Epub 2024 May 7.
7
It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma.是时候关注了——半乳糖凝集素-9作为胰腺导管腺癌潜在的免疫治疗靶点。
Front Immunol. 2025 Jan 31;16:1495907. doi: 10.3389/fimmu.2025.1495907. eCollection 2025.
8
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.调控胰腺导管腺癌免疫治疗抵抗的机制。
Front Immunol. 2021 Jan 28;11:613815. doi: 10.3389/fimmu.2020.613815. eCollection 2020.
9
Immunotherapy for pancreatic ductal adenocarcinoma.胰腺癌的免疫治疗。
J Surg Oncol. 2021 Mar;123(3):751-759. doi: 10.1002/jso.26312.
10
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.胰腺导管腺癌：肿瘤微环境中良好和不良免疫“警察”之间的严重失衡。
Front Immunol. 2018 May 14;9:1044. doi: 10.3389/fimmu.2018.01044. eCollection 2018.
引用本文的文献
1
Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics.胰腺腺癌中的免疫细胞和检查点：与临床和病理特征的关联。
PLoS One. 2024 Jul 2;19(7):e0305648. doi: 10.1371/journal.pone.0305648. eCollection 2024.
2
Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities.半乳糖凝集素-1 在胰腺导管腺癌中的作用：连接肿瘤生物学、免疫逃逸和治疗机会。
Int J Mol Sci. 2023 Oct 24;24(21):15500. doi: 10.3390/ijms242115500.
3
Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities.攻克胰腺导管腺癌中的纤维化堡垒：挑战与机遇
Cancers (Basel). 2023 Apr 18;15(8):2354. doi: 10.3390/cancers15082354.
4
PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer.PCSK9 调节肺癌免疫检查点治疗的疗效。
Front Immunol. 2023 Mar 21;14:1142428. doi: 10.3389/fimmu.2023.1142428. eCollection 2023.
5
The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms.hPRDX5 对胰腺癌的抗肿瘤活性及其可能机制。
Braz J Med Biol Res. 2022 Sep 12;55:e12324. doi: 10.1590/1414-431X2022e12324. eCollection 2022.
6
Conditioned media of pancreatic cancer cells and pancreatic stellate cells induce myeloid-derived suppressor cells differentiation and lymphocytes suppression.胰腺癌细胞和胰腺星状细胞的条件培养基诱导髓源性抑制细胞分化和淋巴细胞抑制。
Sci Rep. 2022 Jul 19;12(1):12315. doi: 10.1038/s41598-022-16671-9.
7
The Liver Pre-Metastatic Niche in Pancreatic Cancer: A Potential Opportunity for Intervention.胰腺癌中的肝脏前转移生态位：一个潜在的干预机会。
Cancers (Basel). 2022 Jun 20;14(12):3028. doi: 10.3390/cancers14123028.
8
Effects of hyperinsulinemia on pancreatic cancer development and the immune microenvironment revealed through single-cell transcriptomics.通过单细胞转录组学揭示高胰岛素血症对胰腺癌发展及免疫微环境的影响。
Cancer Metab. 2022 Feb 21;10(1):5. doi: 10.1186/s40170-022-00282-z.
9
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer.肿瘤内注射 TLR9 激动剂可促进免疫许可微环境转变，并与抗 PD-1 联合在胰腺癌中产生协同抗肿瘤活性。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002876.
10
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.自然杀伤细胞与肿瘤微环境中的髓系来源抑制细胞的相互作用及其对癌症免疫治疗的影响。
Front Immunol. 2021 May 5;12:633205. doi: 10.3389/fimmu.2021.633205. eCollection 2021.
本文引用的文献
1
The role of apoptosis in the pathology of pancreatic cancer.细胞凋亡在胰腺癌病理中的作用。
Cancers (Basel). 2010 Dec 23;3(1):1-16. doi: 10.3390/cancers3010001.
2
Galectin-1 secreted by activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an in vitro study on the microenvironment of pancreatic ductal adenocarcinoma.星型细胞激活后在胰腺导管腺癌基质中分泌的半乳糖凝集素-1促进胰腺癌细胞的增殖和侵袭：胰腺导管腺癌微环境的体外研究。
Pancreas. 2011 Aug;40(6):832-9. doi: 10.1097/MPA.0b013e318217945e.
3
Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.胰腺导管腺癌小鼠缺乏黏蛋白 1 会导致肿瘤生长和转移的严重缺陷。
Cancer Res. 2011 Jul 1;71(13):4432-42. doi: 10.1158/0008-5472.CAN-10-4439. Epub 2011 May 10.
4
Neuropilin and neuropilin associated molecules as new molecular targets in pancreatic adenocarcinoma.神经纤毛蛋白和神经纤毛相关分子作为胰腺腺癌的新分子靶点。
Anticancer Agents Med Chem. 2011 Jun;11(5):442-7. doi: 10.2174/187152011795677481.
5
Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.胰岛素样生长因子信号作为胰腺癌的治疗靶点。
Anticancer Agents Med Chem. 2011 Jun;11(5):427-33. doi: 10.2174/187152011795677454.
6
Defining new paradigms for the treatment of pancreatic cancer.为胰腺癌的治疗定义新范式。
Curr Treat Options Oncol. 2011 Jun;12(2):111-25. doi: 10.1007/s11864-011-0150-8.
7
Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma.中性粒细胞来源的 MMP-9 是胰腺导管腺癌血管生成开关中 VEGF 独立的功能成分。
Angiogenesis. 2011 Sep;14(3):235-43. doi: 10.1007/s10456-011-9207-3. Epub 2011 Mar 26.
8
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.CD40 激动剂可改变肿瘤基质，并在小鼠和人类中显示出对胰腺癌的疗效。
Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.
9
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.癌症免疫编辑：整合免疫在癌症抑制和促进中的作用。
Science. 2011 Mar 25;331(6024):1565-70. doi: 10.1126/science.1203486.
10
Tissue-based class control: the other side of tolerance.基于组织的分类控制：耐受的另一面。
Nat Rev Immunol. 2011 Mar;11(3):221-30. doi: 10.1038/nri2940.
Zotero 插件